Overview
IBIO market data
Price History
No market bars yet for IBIO. This page will populate once the next provider sweep lands.
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for IBIO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — iBio, Inc. (IBIO)SEC EDGAR · Jul 17, 2026, 8:08 PM
iBio Announces New Preclinical Data From Obese Non-Human Primate Study Evaluating IBIO-610, Activin E Antibody CandidateBenzinga · Jul 1, 2026, 11:15 AM
Raymond James Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $5Benzinga · Jun 8, 2026, 6:00 PM
iBio Begins Human Testing of Obesity Drug Candidate, First Patient Dosed in Company's Initial Clinical TrialBenzinga · Jun 2, 2026, 11:05 AM
iBio Q3 EPS $(0.07) Misses $(0.06) EstimateBenzinga · May 12, 2026, 9:10 PM